

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Delgocitinib for treating moderate to severe chronic hand eczema ID6408

## Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Leo Pharma (delgocitinib)	All Wales Therapeutics and Toxicology
Loo i Haima (doigeoidhlib)	Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Changing Faces	British National Formulary
Eczema Outreach Support	Care Quality Commission
Let's face it	Department of Health - Northern Ireland
National Eczema Society	Healthcare Improvement Scotland
South Asian Health Foundation	<ul> <li>Medicines and Healthcare products</li> </ul>
Specialised Healthcare Alliance	Regulatory Agency
	National Association of Primary Care
Healthcare professional groups	National Pharmacy Association
British Association of Dermatologists	NHS Confederation
British Dermatological Nursing Group	Scottish Medicines Consortium
<ul><li>British Geriatrics Society</li><li>British Skin Foundation</li></ul>	Welsh Government
D ::: 1 O : 1 C O 1	<ul> <li>Welsh Health Specialised Services Committee</li> </ul>
<ul> <li>British Society for Cutaneous Allergy</li> <li>Neonatal and Paediatric Pharmacists</li> </ul>	Committee
Group	Possible comparator companies
Primary Care Dermatology Society	<ul> <li>AAH Pharmaceuticals (alitretinoin,</li> </ul>
<ul> <li>Royal College of General Practitioners</li> </ul>	tacrolimus)
Royal College of Nursing	Accord UK (tacrolimus)
Royal College of Paediatrics and Child	Advanz Pharma (methotrexate)
Health	Aspen (azathioprine, mycophenolate
Royal College of Pathologists	mofetil)Cipla UK (methotrexate)
Royal College of Physicians	<ul> <li>Dexcel Pharma (ciclosporin)</li> </ul>
Royal Pharmaceutical Society	Ennogen Healthcare (alitretinoin)
Royal College of Radiologists	GlaxoSmithKline (alitretinoin)
Royal Society of Medicine	Hospira (methotrexate)
St John's Institute of Dermatology	Leo Pharma (tacrolimus)
UK Clinical Pharmacy Association	Medac (methotrexate)
Oth area	Medihealth (tacrolimus)
Others	Morningside Healthcare (methotrexate)
Department of Health and Social Care     Health Technology (Males (UTM))	Mylan (azathioprine; ciclosporin,  mygaphanolata mafatil)
Health Technology Wales (HTW)  Single stakeholder list for the evaluation of delegation in the second stakeholder.	mycophenolate mofetil)

Final stakeholder list for the evaluation of delgocitinib for treating moderate to severe chronic hand eczema ID6408



Consultees	Commentators (no right to submit or appeal)
NHS England	<ul> <li>Nordic Pharma (methotrexate)</li> <li>Nova (azathioprine; mycophenolate mofetil)</li> <li>Novartis (ciclosporin)</li> <li>Orion Pharma (methotrexate)</li> <li>Rosemont Pharmaceuticals (methotrexate)</li> <li>Sandoz (methotrexate)</li> <li>Santen UK (ciclosporin)</li> <li>Strides Pharma (azathioprine, mycophenolate mofetil)</li> <li>Teva UK (tacrolimus)</li> <li>Tillomed Laboratories (azathioprine, mycophenolate mofetil)</li> <li>Viatris (pimecrolimus)</li> <li>Relevant research groups</li> <li>Centre of Evidence-based Dermatology, University of Nottingham</li> <li>Cochrane Skin Group</li> <li>Dermatrust</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Final stakeholder list for the evaluation of delgocitinib for treating moderate to severe chronic hand eczema ID6408



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.